Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
| Revenue (TTM) | $4.09B |
| Gross Profit (TTM) | $1.34B |
| EBITDA | $560.00M |
| Operating Margin | 3.01% |
| Return on Equity | -50.20% |
| Return on Assets | 1.61% |
| Revenue/Share (TTM) | $29.39 |
| Book Value | $17.58 |
| Price-to-Book | 0.89 |
| Price-to-Sales (TTM) | 0.54 |
| EV/Revenue | 1.232 |
| EV/EBITDA | 10.21 |
| Quarterly Earnings Growth (YoY) | -63.60% |
| Quarterly Revenue Growth (YoY) | -5.20% |
| Shares Outstanding | $138.80M |
| Float | $138.10M |
| % Insiders | 0.39% |
| % Institutions | 114.12% |
Volatility is currently contracting
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo (PRGO) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.8 per share a year ago.
Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands Infant Formula divestiture expected to simplify portfolio and sharpen focus on higher-return consumer self care categories; strategic review of Oral Care business remains ongoing Updated full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe DUBLIN, Nov. 4, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products, today announced financial results from continuing operations for the third quarter ended September 26, 2026. "Our Three-S plan is delivering continued progress in the areas of the business within our control," said Albert Manzone, Interim President and Chief Executive Officer.
DUBLIN, Oct. 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on December 15, 2026, to shareholders of record on November 27, 2026.
Advances Streamline pillar of Perrigo's Three-S plan through portfolio simplification Furthers Perrigo's evolution into a simpler, more focused consumer self-care company Expected to enhance Perrigo's margin profile and eliminate significant expected future capital expenditures Aligns reported results more closely with the financial profile of Core Perrigo MeridianMade's infant-grade, American manufacturing infrastructure and operating capabilities will support the continued supply of safe, high-quality, and affordable infant nutrition DUBLIN, Oct. 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or "the Company"), a leading provider of consumer self-care products, today announced that it has entered into a definitive agreement pursuant to which MeridianMade, an American contract manufacturing platform dedicated to infant nutrition, will acquire Perrigo's Infant Formula business for total consideration of up to $175 million. The transaction consists of $40 million in cash at closing and up to an additional $135 million contingent on the achievement of future performance milestones through 2030.
DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will hold a conference call beginning at 8:30 a.m.
Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026. About Perrigo Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe.
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRGO and any ticker you trade — then tracks every position and per-strategy win rate.
